eXIthera is a clinical stage biotech company focused on developing small molecule anti-thrombotics to inhibit Factor Xla, an important enzyme in the blood coagulation pathway.
Inappropriately activated clotting can lead to serious consequences including venous thromboembolism, deep vein thrombosis, stroke and heart attack. eXIthera's novel development candidates are expected to prevent thrombosis without causing bleeding and without the need for a reversal agent, the primary complications associated with all currently approved products. eXIthera has both parenteral and oral programs in development to facilitate a smooth transition from inpatient to outpatient treatment settings.
eXIthera Pharmaceuticals is a clinical stage biotech company focused on discovering and developing Factor XIa inhibitors for the prevention of thrombosis.
Blood coagulation is an important part of the host defense mechanism required for repair and maintenance of the circulatory system. This complex and multifactorial process has been described to contain two parallel but distinct pathways; hemostasis and thrombosis.